Statistical analysis of apoptotic response to BNZ-1 between responders and nonresponders
| . | 1-month treatment . | Extended treatment . | Washout . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Predose . | Day 2 . | Day 8 . | Day 15 . | Day 29 . | Week 9 . | Week 13 . | Week 17 . | Follow-up week 2 . | Follow-up week 4 . | Follow-up week 6 . | |
| Responders | |||||||||||
| Mean ± SEM (%) | 9.65 ± 3.12 | 56.95 ± 6.18 | 32.28 ± 4.91 | 42.75 ± 4.05 | 51.13 ± 2.73 | 19.00 ± 6.44 | 34.32 ± 8.77 | 19.20 ± 6.86 | 36.50 ± 5.74 | 23.15 ± 7.92 | 18.20 ± 2.81 |
| P value (compared with predose) | < .001 | .008 | < .001 | < .001 | .253 | .038 | .273 | .01 | .164 | .067 | |
| n | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Nonresponders | |||||||||||
| Mean ± SEM (%) | 29.78 ± 5.82 | 49.80 ± 4.87 | 35.10 ± 5.52 | 36.95 ± 5.79 | 41.50 ± 5.93 | 43.51 ± 5.74 | 37.20 ± 5.53 | 31.32 ± 7.46 | 30.30 ± 5.63 | 16.2 ± 3.10 | 26.70 ± 7.19 |
| P value (compared with predose) | .013 | .514 | .389 | .168 | .113 | .396 | .872 | .951 | .152 | .762 | |
| n | 16 | 16 | 15 | 16 | 16 | 12 | 10 | 10 | 12 | 7 | 7 |
| . | 1-month treatment . | Extended treatment . | Washout . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Predose . | Day 2 . | Day 8 . | Day 15 . | Day 29 . | Week 9 . | Week 13 . | Week 17 . | Follow-up week 2 . | Follow-up week 4 . | Follow-up week 6 . | |
| Responders | |||||||||||
| Mean ± SEM (%) | 9.65 ± 3.12 | 56.95 ± 6.18 | 32.28 ± 4.91 | 42.75 ± 4.05 | 51.13 ± 2.73 | 19.00 ± 6.44 | 34.32 ± 8.77 | 19.20 ± 6.86 | 36.50 ± 5.74 | 23.15 ± 7.92 | 18.20 ± 2.81 |
| P value (compared with predose) | < .001 | .008 | < .001 | < .001 | .253 | .038 | .273 | .01 | .164 | .067 | |
| n | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Nonresponders | |||||||||||
| Mean ± SEM (%) | 29.78 ± 5.82 | 49.80 ± 4.87 | 35.10 ± 5.52 | 36.95 ± 5.79 | 41.50 ± 5.93 | 43.51 ± 5.74 | 37.20 ± 5.53 | 31.32 ± 7.46 | 30.30 ± 5.63 | 16.2 ± 3.10 | 26.70 ± 7.19 |
| P value (compared with predose) | .013 | .514 | .389 | .168 | .113 | .396 | .872 | .951 | .152 | .762 | |
| n | 16 | 16 | 15 | 16 | 16 | 12 | 10 | 10 | 12 | 7 | 7 |
Averages and standard deviations of the percentages of apoptotic cells within each subset (CD4 T cells or T-LGLL cells) were calculated.
Average (percentage of the apoptotic cells within each subset) on the given day of the treatment was compared with that of day 1 (pretreatment), and Student t test was performed to determine the P values to check whether the difference was significant (P < .05 shown in italic).
Numbers given in the table are the P values of each comparison.
Note that apoptotic percentages in responders showed significant difference from that at pretreatment at all times during treatment and returned to baseline during the washout, whereas that in nonresponders was significantly elevated from that at pretreatment then subsided quickly, suggesting that the sustained apoptotic response of T-LGLL cells may differentiate responders from nonresponders.